Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sciwind Biosciences and Verdiva Bio Enter Global Licensing Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Sciwind Biosciences and Verdiva Bio Enter Global Licensing Agreement

Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its portfolio of metabolic disease therapies.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing therapies to treat metabolic diseases, has announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited, a clinical-stage biopharmaceutical company specialized in developing treatments for obesity and other cardiometabolic disorders.

The partnered portfolio under this collaboration includes:

  • Oral Ecnoglutide (Ecnoglutide Oral, XW004): A phase 2-ready, once-weekly oral GLP-1 receptor agonist
  • Oral Amylin Receptor Agonist (Amylin RA): A once-weekly long-acting, oral amylin receptor agonist in IND-enabling studies
  • Subcutaneous injectable Amylin Receptor Agonist (Amylin RA): A long-acting, amylin receptor agonist in IND-enabling studies

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to develop, manufacture and commercialize these products in all other regions.

Under the agreement, Sciwind receives an upfront consideration totaling approximately $70 million, and is eligible to receive more than $2.4 billion in milestone payments for development, regulatory approvals and commercialization of above-mentioned partnered programs, Additionally, Sciwind is also eligible to receive tiered royalties on future product sales outside of greater China and South Korea. Furthermore, the two companies will collaborate on additional preclinical stage programs, and Sciwind is eligible to receive milestones and royalty payments based on the advancement of those programs.

With this collaboration, Verdiva Bio plans to advance the development of innovative therapies through a series of clinical studies involving both monotherapy and combination treatments. This collaboration highlights the global commercialization potential of Sciwind’s pipeline and lays a foundation for the worldwide development and potential commercialization of key products like Ecnoglutide.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics